Table 2 List of previous and current studies conducted by the ER-RCBP
ER-RCBP major studies’ recruitment, retention, and relevant activities and skills | ||||||
|---|---|---|---|---|---|---|
Study | Years | Recruitment period | N | Follow-up period | Annual retention | Relevant activities and skills |
Cervical cancer screening studies | ||||||
RWISA | 2005–2010 | 6 months | 970 | Q6m for 5 years | 93% | Cytology, HPV testing, colpo, LEEP, biorepository |
HPV demonstration project with CareHPV study (CxCa see and Treat, clinic- and community-based) | 2009–2010 | 1 year | 3100 | Not applicable | NA | HPV, VIA, Cryotherapy, biorepository, CHW |
Optimal methods for CxCa prevention among WWH | 2015–2020 | 2 years | 5061 | 2 years f/u of screen + WWH | 89–91% | Xpert HPV, E6/7, p16, Ki67, image capture for AVE, colposcopy, thermal ablation, LEEP, biorepository, CHW |
Anal high-risk human papillomavirus (hrHPV) and ASIL in Rwandan WWH with cervical HPV (pilot) | 2019 | 1 month | 50 | NA | NA | Anal pap, HRA, anal/cervical HPV by Ampfire, biorepository |
Other studies in people living with HIV | ||||||
Prevalence and incidence of HPV, HIV, and anal disease in Rwandan MSM | 2016–now | 1 year | 350 | Q6m × 8 | 91% | ACASI, anal, penile specimens, HRA, Ampfire, biorepository, anal cytology |
CA-IeDEA Sentinel Research Network | 2020–now | 9 months | 600 | 6 months, 12 months, 24 months | 99% | POC testing, fibroscan, ACASI, REDCap, biorepository |
Reducing time to spaced-out appointments for newly diagnosed people living with HIV (pilot) | 2020–2022 | 6 months | 90 | 6 months, 12 months | 97% | Clinical trial (pilot), REDCap |
Cancer Registration | 2010–now | Ongoing | 19,906 | NA | NA | Senior cancer registrars/trainer, transferred to RBC 2018; registry match with HIV; access to data |
CA-IeDEA | 2011–now | Ongoing | 35,000 | Ongoing | 94% | Secondary data extracted from EMR |